Summit Therapeutics (SMMT) Treasury Shares (2020 - 2026)

Summit Therapeutics' (SMMT) quarterly Treasury Shares came in at $730000.0 in Q2 2026, little changed on a QoQ basis from $730000.0 in Q1 2026.

Summit Therapeutics (SMMT) Treasury Shares (2020 - 2026) Analysis & Trends

Summit Therapeutics (SMMT) has 2 years of Treasury Shares data on file, last reported at $730000.0 in Q2 2026.

Quarterly Treasury Shares changed N/A year-over-year to $730000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $730000.0 (changed N/A YoY) and the FY2020 annual result came in at $26923.0, changed N/A from the prior year.
Treasury Shares held at $730000.0 in Q2 2026, from $730000.0 in the prior quarter.
In the past five years, Treasury Shares ranged from a high of $730000.0 in Q1 2026 to a low of $730000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	5.08 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	2.72 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	92,219.00
10	Summit Therapeutics	10.59 Bn	9.90 Bn	-	730,000.00

Download Data